RecruitingInterventionalPhase 3Updated May 11, 2023
Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical... | NCT02789189 | Trialant
Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical Trail
ClinicalTrials.gov ID
NCT02789189
Lead Sponsor
Sun Yat-sen UniversityOTHER
Overall Status
Terminated
Study Type
Interventional
Phase
Phase 2
Enrollment
60Estimated
Last Update Posted
Sep 6, 2019Actual
Start Date
Jun 2016
Primary Completion Date
Sep 4, 2019Actual
Brief Summary
The purpose of this single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of nedaplatin combined with gemcitabine in the treatment of recurrent and metastatic nasopharyngeal carcinoma
Recurrent and Metastatic Nasopharyngeal Carcinoma
nedaplatin and gemcitabine
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
biopsy proved nasopharyngeal carcinoma; stage IVc according to Union for International Cancer Control (UICC) edition VII,or recurrent disease after chemotherapy and/or radiotherapy; 18 years or older; without other malignancy; proper functioning of the major organs.
Exclusion Criteria:
allergic to nedaplatin and/or gemcitabine; female within gestation period or lactation; patients received drug of other clinical trail within 3 months.